Literature DB >> 6224556

Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.

S C Schold, D D Bigner.   

Abstract

Five human glioma tumor lines were transplanted subcutaneously in athymic nude mice. Three of the lines (D-54 MG, U-118 MG, and U-251 MG) were derived from permanent human glioma cell lines, while the other two lines (N-456 and N-519) were established as direct xenografts in mice. Growth rates varied among the lines, but all were treated at a common average tumor volume of 200-300 mm3. Three drugs of known clinical activity against human anaplastic glial tumors were tested in this system. Procarbazine (PCB) produced significant responses in all five tumor lines, carmustine produced significant growth delays in two, and mithramycin produced a slight growth delay in only one. A carmustine-PCB combination produced a greater therapeutic effect than either agent alone against D-54 MG, but the combination was no more effective than PCB alone against U-118 MG. These results parallel clinical experience and indicate that this is a useful model for testing agents of potential activity in brain tumor therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224556

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  9 in total

Review 1.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

Review 2.  Monoclonal antibodies in neuro-oncology.

Authors:  D Stavrou
Journal:  Neurosurg Rev       Date:  1990       Impact factor: 3.042

3.  A new rat brain tumor model: glioma disseminated via the cerebral spinal fluid pathways.

Authors:  A B Rewers; E S Redgate; M Deutsch; E R Fisher; S S Boggs
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

Review 4.  What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.

Authors:  S Amarasingh; M R Macleod; I R Whittle
Journal:  J Neurooncol       Date:  2008-09-24       Impact factor: 4.130

5.  Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.

Authors:  William J Bodell; Donald D Giannini; Saira Singh; Dennis Pietronigro; Victor A Levin
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

6.  Therapeutic response to taxol of six human tumors xenografted into nude mice.

Authors:  J Riondel; M Jacrot; F Picot; H Beriel; C Mouriquand; P Potier
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Interstitial infusion of carmustine in the rat brain stem with systemic administration of O6-benzylguanine.

Authors:  Mark M Souweidane; Giuseppe Occhiogrosso; Erika B Mark; Mark A Edgar; Ira J Dunkel
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

Review 8.  In vivo models of primary brain tumors: pitfalls and perspectives.

Authors:  Peter C Huszthy; Inderjit Daphu; Simone P Niclou; Daniel Stieber; Janice M Nigro; Per Ø Sakariassen; Hrvoje Miletic; Frits Thorsen; Rolf Bjerkvig
Journal:  Neuro Oncol       Date:  2012-06-07       Impact factor: 12.300

9.  Circular RNA hsa_circ_0076248 promotes oncogenesis of glioma by sponging miR-181a to modulate SIRT1 expression.

Authors:  Bingxi Lei; Yutao Huang; Zhiwei Zhou; Yiying Zhao; Ashish Jung Thapa; Wenpeng Li; Wangqing Cai; Yuefei Deng
Journal:  J Cell Biochem       Date:  2018-12-03       Impact factor: 4.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.